281 related articles for article (PubMed ID: 26873871)
1. Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus.
Quan H; Zhang H; Wei W; Fang T
J Diabetes Complications; 2016; 30(4):686-92. PubMed ID: 26873871
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Gadde KM; Vetter ML; Iqbal N; Hardy E; Öhman P;
Diabetes Obes Metab; 2017 Jul; 19(7):979-988. PubMed ID: 28205322
[TBL] [Abstract][Full Text] [Related]
3. [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
Pujante Alarcón P; Hellín Gil MD; Román LM; Ferrer Gómez M; García Zafra MV; Tébar Massó J
Med Clin (Barc); 2012 Dec; 139(13):572-8. PubMed ID: 22209597
[TBL] [Abstract][Full Text] [Related]
4. Effects of exenatide on metabolic parameters/control in obese Japanese patients with type 2 diabetes.
Tokuda M; Katsuno T; Ochi F; Miyakoshi K; Kusunoki Y; Murai K; Miuchi M; Hamaguchi T; Miyagawa J; Namba M
Endocr J; 2014; 61(4):365-72. PubMed ID: 24452017
[TBL] [Abstract][Full Text] [Related]
5. Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.
Lingvay I; Harris S; Jaeckel E; Chandarana K; Ranthe MF; Jódar E
Diabetes Obes Metab; 2018 Jan; 20(1):200-205. PubMed ID: 28643425
[TBL] [Abstract][Full Text] [Related]
6. Exenatide: new drug. Type 2 diabetes for some overweight patients.
Prescrire Int; 2007 Dec; 16(92):228-31. PubMed ID: 18087791
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
Wysham CH; Rosenstock J; Vetter ML; Dong F; Öhman P; Iqbal N
Diabetes Obes Metab; 2018 Jan; 20(1):165-172. PubMed ID: 28685973
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.
Yuan GH; Song WL; Huang YY; Guo XH; Gao Y
Chin Med J (Engl); 2012 Aug; 125(15):2677-81. PubMed ID: 22931974
[TBL] [Abstract][Full Text] [Related]
9. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
de Boer SA; Lefrandt JD; Petersen JF; Boersma HH; Mulder DJ; Hoogenberg K
Int J Clin Pharm; 2016 Feb; 38(1):144-51. PubMed ID: 26597956
[TBL] [Abstract][Full Text] [Related]
10. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.
Shao N; Kuang HY; Hao M; Gao XY; Lin WJ; Zou W
Diabetes Metab Res Rev; 2014 Sep; 30(6):521-9. PubMed ID: 24823873
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
[TBL] [Abstract][Full Text] [Related]
12. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
[TBL] [Abstract][Full Text] [Related]
13. Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly.
Shaw JE; Gallwitz B; Han J; Hardy E; Schernthaner G
Diabetes Obes Metab; 2017 Dec; 19(12):1793-1797. PubMed ID: 28573708
[TBL] [Abstract][Full Text] [Related]
14. [Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
Lecube A; Bueno M; Suárez X
Med Clin (Barc); 2014 Sep; 143 Suppl 2():23-7. PubMed ID: 25437462
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
16. Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide.
Pencek R; Brunell SC; Li Y; Hoogwerf BJ; Malone J
Endocr Pract; 2012; 18(2):227-37. PubMed ID: 22446132
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.
Ratner RE; Maggs D; Nielsen LL; Stonehouse AH; Poon T; Zhang B; Bicsak TA; Brodows RG; Kim DD
Diabetes Obes Metab; 2006 Jul; 8(4):419-28. PubMed ID: 16776749
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
Lundkvist P; Pereira MJ; Katsogiannos P; Sjöström CD; Johnsson E; Eriksson JW
Diabetes Obes Metab; 2017 Sep; 19(9):1276-1288. PubMed ID: 28345814
[TBL] [Abstract][Full Text] [Related]
19. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
Norwood P; Liutkus JF; Haber H; Pintilei E; Boardman MK; Trautmann ME
Clin Ther; 2012 Oct; 34(10):2082-90. PubMed ID: 23031623
[TBL] [Abstract][Full Text] [Related]
20. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.
Simó R; Guerci B; Schernthaner G; Gallwitz B; Rosas-Guzmàn J; Dotta F; Festa A; Zhou M; Kiljański J
Cardiovasc Diabetol; 2015 Sep; 14():116. PubMed ID: 26338040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
